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Design of experiments (DoE)
A B S T R A C T
A capillary zone electrophoresis (CZE) method with UV detection was developed for the quantification of the
E.coli L-asparaginase (L-ASNase) and its acidic variants. During the initial method development, a variety of
experimental conditions were screened. Subsequently, a Design of Experiments (DoE) was used to optimize the
pH and concentration of the selected background electrolyte (BGE) containing both TRIS and boric acid.
Optimization was performed taking into account both the separation efficiency of L-ASNase and its acidic var-
iants as well as overall method robustness. A repeatable separation between E.coli L-ASNase and its acidic
variants was achieved on a bare fused silica capillary in combination with a BGE consisting of both 400mM TRIS
and boric acid. The method was validated for linearity, accuracy, precision, LOD, LOQ and robustness. The
recovery for L-ASNase was 97.9–104.4% with a precision RSD of 1.5–3.2%, while the recovery of impurities was
92.1–109.8% with a RSD of 1.7–4.6%. The quantification limit was 1.9% (m/m). Moreover, the CZE-UV method
was applied to determine the degradation rate in the presence of ammonium bicarbonate, confirming the
suitability of the method. The degraded, partially charged L-ASNase was evaluated for its in-vitro enzymatic
activity showing an insignificant different enzyme activity compared to the unmodified sample.
1. Introduction
L-asparaginase (L-ASNase) is a tetrameric enzyme used in pediatric
treatment of acute lymphoblastic leukaemia (ALL) [1]. Clinically used
L-ASNase preparations are currently derived from two bacterial sources:
Escherichia coli and Erwinia chrysanthemi [1], with a tetrameric mole-
cular weight (MW) of 136,320 Da resp. 140,320 Da and an isoelectric
point (pI) of 4.9 resp. 8.6 [2–4]. Like other biopharmaceuticals, L-AS-
Nase is prone to modifications during its bacterial production as well as
pharmaceutical processing and storage [5]. Also, during the preclinical
and clinical trials, consistency in the nature and quantity of these
modifications is of critical importance for a successful development of
the originator medicines as well as of the biosimilars. The consistency
of these modifications is also crucial for the novel L- ASNase formula-
tions under development [6,7]. As these protein modifications are
known to change the physicochemical, immunochemical, biological
and pharmacological properties, which may contribute to adverse ef-
fects, it is important to characterize this heterogeneity [8].
Charge variants are an important type of protein heterogeneity and
typically consist of acidic variants (e.g. sialylation and deamidation)
and basic variants (e.g. succinimide formation and oxidation of some
amino acid side chains [Met, Cys, Lys, His, Trp] and C-terminal Lys
cleavage) [6,9]. Deamidation is one of the most frequent acidic de-
gradation pathways and is common in Asn residues [10]. The Asn
deamidation reaction results in a cyclic succinimide, which is further
hydrolysed to form an Asp and isoAsp mixture (with a mass increase of
1 Da from 114 Da for Asn to 115 Da for Asp) with the release of am-
monia [10]. This leads to a decrease of the isoelectric point (pI) due to
the change in residue charge from neutral to the acidic carboxylate.
Moreover, deamidation generally leads to loss of biological function,
secondary and tertiary structure and stability [11,12]. However, dea-
midated variants of Erwinia L-ASNase (deamidated site: Asn281) are
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reported to retain their in-vitro enzymatic activity [13]. No studies
concerning about the enzyme activity of the deamidated variants of
E.coli L-ASNase have been reported yet. Charge variants of proteins can
be analyzed using a variety of techniques for distinct purposes, in-
cluding isoelectric focusing like slab gel isoelectric focusing (IEF) and
capillary isoelectric focusing (CIEF), capillary electrophoresis, ion-ex-
change chromatography (IEX), and mass spectrometric techniques
[14–26]. A traditional method for evaluating the charge variants is the
IEF [14,15]. IEF can provide high-resolution separation of similar
charge variants, but it is time consuming, labor intensive and has an
unsatisfactory quantitation precision. Other techniques reported were
CIEF [14–17] and more recently imaged capillary electrophoresis (iCE)
[18,19]. However, while they allow more quantitative evaluation, these
techniques are still time consuming. Capillary zone electrophoresis
(CZE) has recently been shown to be a suitable technique to char-
acterize protein charge variants due to its high resolution and speed,
low sample consumption and low cost availability of capillaries
[20–22]. The charge variants of Erwinia L-ASNase, such as the deami-
dated variants and the non-deamidated acidic variants, have been
characterized in the recent years by using IEX, CIEF, liquid chromato-
graphy tandem-mass spectrometry (LC-MS/MS) of proteolytic digests,
and structural techniques including circular dichroism (CD), small-
angle X-ray scattering (SAXS) and ion-mobility mass spectrometry (IM-
MS) [25–29]. The charge variants of E.coli L-ASNase has been much less
studied compared to that of Erwinia L-ASNase; some investigations have
been reported such as the characterization of succinylated charge var-
iants by using ultraviolet spectroscopy, fluorescence spectroscopy and
CD, and the identification of deamidated variants by LC-MS/MS of
proteolytic digests [25,30]. Regarding to the CZE-UV method, up till
now, only one CZE-UV method for Erwinia L-ASNase is briefly reported
without analytical details [13]. Moreover, the acidic variants were not
separated. No CZE-UV methods for determining E.coli L-ASNase and
charge variants have ever been reported.
In this study, a systematic development of a CZE-UV method for the
quantification of L-ASNase as well as of the acidic variants of E.coli L-
ASNase is presented. After an initial screening investigation, the
method was optimized using experimental designs (DoE) following the
quality-by-design (QbD) concept to define the design space. The opti-
mized method was further formally validated and applied on different




Hydrochloric acid, TRIS (Trizma®base), boric acid, sodium hydro-
xide, ammonium bicarbonate, potassium iodide, mercury (II) iodide
and trichloroacetic acid (TCA) were purchased from Sigma-Aldrich (St.
Louis, Missouri, USA). Potassium phosphate monobasic and L-aspar-
agine monohydrate were obtained from Merck (Darmstadt, Germany).
Ammonium chloride was purchased from UCB (Brussels, Belgium). All
chemicals were analytical grade. Paronal® samples, i.e. E.coli L-ASNase
preparation without excipients (label claim of 10,000 IU per vial;
Kyowa Hakko Kiri Co., Ltd.) (Tokyo, Japan), were obtained from
Takeda Pharmaceutical Co., Ltd. (Brussels, Belgium). In the absence of a
formal reference standard for the selective assay of L-ASNase, batch
10858381 was used as laboratory reference material, which contained
79.1% of active pharmaceutical ingredient (API), 14.4% of impurity 1,
4.5% of impurity 2% and 2.0% of impurity 3, based on peak decon-
volution and area normalization (see Section 2.5) [31–33].
2.2. Sample and BGE preparation
For the initial development and the following optimization, 1mg/
mL L-ASNase in water was applied. In the initial development, BGEs of
500mM/500mM, 600mM/600mM and 800mM/800mM TRIS/boric
acid at different pH values (pH 7.5, pH 8.0, pH 8.5, pH 8.25, pH 8.75
and pH 9.5), and 1M/1M TRIS/boric acid (pH 8.5 and pH 8.0) were
prepared. Moreover, potassium tetraborate solution at fixed con-
centration of 50mM (pH 7.0, pH 8.0, pH 9.0 and pH 10.0), boric acid
solution (50mM, adjusted to pH 10), and TRIS solution (25mM, pH
8.0) and (50mM, pH 8.0) were prepared. Additionally, 200mM/
200mM TRIS/tricine (pH 8.24) was also prepared. All above BGEs were
tested on the bare fused-silica capillary. In the entire study, 1M hy-
drochloric acid or 1M sodium hydroxide was applied, when the pH
adjustment is required.
Regarding the method optimization, a three level central composite
design (CCD) with three center points is employed to define the design
space of the pH and concentration of BGE (Supplementary material
Table 1) [34]. Each experimental block consisting of 11 runs, was
performed in triplicate. The factors and their ranges were 1) con-
centration of TRIS/boric acid ranging from 100mM/100–600mM/
600mM, 2) pH of TRIS/boric acid ranging from pH 8.0 to pH 9.0. For
these experiments, 100mM/100mM TRIS/boric acid (pH 8, pH 8.5 and
pH 9), 350mM/350mM TRIS/boric acid (pH 8, pH 8.5 and pH 9) and
600mM/600mM TRIS/boric acid (pH 8, pH 8.5 and pH 9) were ap-
plied. For the final method, the running BGE consisted of 400mM TRIS
and 400mM boric acid (pH unadjusted, the measured pH value was pH
8.4).
The final method was applied on different modified (degraded)
samples to test the modification rate. 1.0 mg/mL L-ASNase samples
were stored in 1% NH4HCO3 (m/v), and incubated at 37 °C for 0, 8, 16
and 24 h [13,35].
2.3. CE parameters
Proteomelab PA 800 plus CE instrument (Beckman Coulter, Brea,
United States) was used coupled with a diode array detector. In the
method development and validation parts, a bare fused-silica capillary
(Polymicro Technologies, Phoenix, AZ, USA) was used which possessed
an effective length of 20 cm and internal diameter of 50 µm (outer
diameter, 365 µm). Samples were kept at a temperature of 10 °C and
injected at 0.4 psi for 4 s. The separation voltage was 9 kV, and the
polarity was normal. UV absorbance was detected at 214 nm and the
optical window was 200 µm. New fused silica capillaries were pre-
treated with 1M NaOH, water, and BGE subsequently at 20 psi for
20min. Between two consecutive injections, the fused silica capillary
was flushed with 1M NaOH, water and BGE for 2min at 20 psi, re-
spectively.
2.4. Method characteristics
2.4.1. Relative response factor of the acidic L-ASNase species
Neglecting differences in MW of the unmodified L-ASNase and the
acidic species (i.e. amide versus acid), the relative response factor (RRF) of
the acidic species relative to the unmodified L-ASNase is defined by [36]:
As quantitative evaluation of these related impurities can be ac-
complished using the internal normalization procedure, the raw data
(i.e. peak area or height) are to be converted to mass units (i.e. as %).
Therefore, the relative response factor (RRF) needs to be assessed: if
this RRF falls between 0.80 and 1.20, then no consideration for it is
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appropriate reference standards for these impurities, and using mass
and peak balance principles, an estimation of RRF (in UV 214 nm) can
be obtained using unstressed and stressed (degraded) solutions, as de-
monstrated in [36].
2.4.2. Selectivity
The modified L-ASNase sample was prepared by incubating 2.0 mg/
mL L-ASNase in 1% NH4HCO3 at 37 °C for 48 h. The sample was con-
tained in the 2mL Eppendorf tube and the temperature was controlled
by the oven (Binder; Bohemia, USA). The selectivity was evaluated by
the separation (expressed as peak to valley ratio [p/v]) between the API
and the acidic impurities in modified L-ASNase sample. The p/v is the
ratio between the peak height of impurity 1 and the valley between API
and impurity 1, defined according to the Ph. Eur [37]. The definition of
impurity 1 can be found in Section 3.1.
2.4.3. Linearity and range
Regarding L-ASNase, 2.5mg reference material (corresponding to
1.98mg/mL API, seen the impurities present) was dissolved in 1.0 mL
of water. 20.0, 40.0, 80.0 and 120.0 µL of above solution were diluted
to 200.0 µL to obtain final concentrations representing 25% (0.198mg/
mL), 50% (0.396mg/mL), 100% (0.791mg/mL) and 150% (1.187mg/
mL) of L-ASNase concentration of 0.791mg/mL. For impurity 1, 27.3,
54.3, 108.8, 163.0 and 326.0 µL of the 2.0mg/mL modified L-ASNase
solution was diluted to 500.0 µL to obtain final concentrations re-
presenting 0.036, 0.072, 0.144, 0.215 and 0.430mg/mL of impurity 1.
Concerning impurity 2, 21.7, 32.6, 43.4, 65.1 and 130.2 µL of the
2.0 mg/mL modified L-ASNase solution was diluted to 500 µL to obtain
final concentrations representing 0.022, 0.034, 0.045, 0.068 and
0.135mg/mL of impurity 2.
2.4.4. Accuracy and precision
The recovery is calculated as the ratio between the concentration
found and the theoretical concentration. The concentration found is
calculated by fitting the obtained peak area values in the equation of
the calibration curve. The preparation of these solutions (each con-
centration in triplicate) is the same as in Section 2.4.3: with respect to L-
ASNase, three reference solutions representing 0.396, 0.791 and
1.187mg/mL of L-ASNase reference solution were used. For impurity 1
and impurity 2, the 2.0mg/mL modified L-ASNase solutions re-
presenting 0.072, 0.144 and 0.215mg/mL of impurity 1 and 0.034,
0.045 and 0.068mg/mL of impurity 2 were used respectively.
2.4.5. LOD and LOQ
For determining the LOD/LOQ of L-ASNase, the 0.198mg/mL L-
ASNase reference solution was used. Concerning impurity 1 and im-
purity 2, the 2.0 mg/mL modified L-ASNase solutions representing
0.036mg/mL of impurity 1 and 0.022mg/mL of impurity 2 were used
(see Section 2.4.3.). Signal is defined as the height of the compounds
peak. Noise is defined as the difference between the highest and lowest
values of the baseline, observed over a distance equal to 5 times the
width at the half-height of the compound peak, situated in the area
after the compound peak.
2.4.6. Robustness evaluation
A three level Plackett-Burman design (PBD) with three center points
was adopted to test the robustness of the applied final method
(Supplementary material Table 2) [38]. The factors were defined as the
pH of BGE ranging between 8.30 and 8.50 and the concentration of BGE
ranging between 395 and 405mM.
2.5. Data analysis
For the DoE, the set-ups and their evaluations were performed by
MODDE 8.0.2 software from Umetrics (Umea, Sweden). In order to
quantify the overlapping peaks, peak deconvolution was applied, using
Gaussian peak algorithm (deconvolution filter of 75; vary peak width)
(PeakFit V4 software; Chicago, United States).
2.6. Enzyme activity of the modified L-ASNase
The functional enzyme activity of the modified L-ASNase samples
(see Section 2.2) was investigated using a previously developed Nessler
method [39]. 1.0mL of each 1.0 mg/mL (250 IU/mL, one 10,000 IU
vial L-ASNase contains 40mg powder) sample was further diluted to
50.0 mL using phosphate buffer pH 7.4 (prepared by using a 0.2M
potassium dihydrogen phosphate and 0.1M sodium hydroxide),
yielding a theoretical 5 IU/mL solution. To 0.1mL of this solution,
1.9 mL of 20mM L-Asn (ligand solution) was added. This reaction was
carried out at 37 °C for 15min and stopped by addition of 0.5mL of
25% TCA. Ammonium chloride solution (50 ppm) was employed as
reference solution. After the reaction with the Nessler reagent, the ab-
sorbance of the sample and reference solution at 450 nm was further
measured as previously reported [39]. Samples were analyzed in du-
plicate.
3. Results
3.1. Initial method development
In the initial development, a bare capillary (effective length of
20 cm; internal diameter of 50 µm) was tested, in order to achieve a CE-
UV method possessing high resolution, short migration time and good
peak shape. Both the low ionic strength BGEs, i.e. potassium tetraborate
(50mM, pH 7.0–10.0), boric acid (50mM, pH 10), and TRIS (25mM,
pH 8.0; 50mM, pH 8.0) and high ionic strength buffers, i.e. 200mM/
200mM TRIS/tricine (pH 8.24) and 500mM/500mM TRIS/boric acid
(pH 8.5), were investigated on this bare fused-silica capillary. These
BGEs were chosen due to their simplicity and the pKa of BGEs com-
ponents. The pH of BGEs is at least one unit higher than the pI (4.9) of
E.coli L-ASNase [4]. Overall, on the bare fused-silica capillary, only the
BGE of TRIS/boric acid could separate the API from its charge im-
purities, and hence was used for further investigation.
The influence of the concentration and pH of the TRIS/boric acid
was further explored on the bare fused-silica capillary, within a con-
centration range from 500mM/500–800mM/800mM and a pH range
from 8.0 to 9.0. Since the pI (4.9) of native E.coli L-ASNase is under
these BGE pH (8.0–9.0), the acidic variants will be more negatively
charged. Thus, the acidic variants will show a longer migration time,
compared to the native L-ASNase, as observed in Fig. 1a. The acidic
impurity closest to the API peak is defined as impurity 1. Increasing the
BGE concentration leads to an improved p/v, going from 1.18
(500mM/500mM) to 1.32 (800mM/800mM), but increases also the
run time. pH increase leads to shorter migration times, but a lower p/v,
varying from 1.41 (pH 8.0) to 1.18 (pH 8.75) (Fig. 1b). The resolution is
defined as peak to valley ratio (p/v) i.e. the ratio between the peak
height of impurity 1 and the valley between API and impurity 1. Con-
sidering the benefits and drawbacks, the concentration and pH of BGE
were further systematically investigated by using DoE.
Moreover, other CE parameters were also investigated on the bare
fused-silica capillary, with 600mM TRIS/600mM boric acid (pH 8.25)
as BGE. Capillary effective lengths of 40 cm, 20 cm and 10 cm were
tested: a sufficiently shorter migration time (maximum 10min) as well
as a sufficient p/v (minimum 1.3) can be obtained on the effective
20 cm length capillary, which was chosen as the final length. Different
separation voltages (i.e. 9, 14, 18, 23, 27 and 30 kV) were tested: since
higher voltages lead to a worse separation, 9 kV was therefore selected.
Cartridge temperature, i.e. 15 and 25 °C, and the optical window, i.e.
200 and 800 µm, leads to similar migration times and peak separations.
Therefore, a lower cartridge temperature of 15 °C and a narrow optical
window of 200 µm was chosen.
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3.2. Method optimization using a QbD philosophy
3.2.1. Critical method attributes (CMAs) and critical method variables
(CMVs)
Design of experiments (DoE), as a key aspect of quality by design
(QbD), is a well-proven characterization approach within analytical
method development. The purpose is to investigate the individual and
combined effects of CMVs on CMAs. According to the observation in the
initial method development, concentration of BGE and pH are chosen as
the critical method variables (CMVs). CMAs are important method
characteristics defined here as: 1) resolution expressed as the peak to
valley ratio between the API and the closest impurity (max); 2) RSD (%)
of migration time of API (min); 3) RSD (%) of peak area of API (min); 4)
migration time of API (min).
3.2.2. Determination of the design space
The primary purpose of the full CCD was to define the design space
where a high resolution, a short and robust migration time, and a robust
peak area can be obtained. By applying multivariate regression ana-
lysis, a fitted full second order model was obtained for the four re-
sponses, given by the following equation:
= + + + + +Y β β X β X β X β X β X X0 1 1 2 2 11 12 22 22 12 1 2
where, Y: the response; β0: the intercept; β1, β2: regression coefficients
of the factors X1 (concentration) and X2 (pH), respectively.
The relationships between the factors and the different responses
are elucidated by regression analysis and indicated by the coefficients
of the regression models. For the peak to valley ratio as response, shown
in Fig. 2a and Supplementary material Table 3, concentration, pH, and
pH*pH and C*pH were the significant factors: concentration is able to
significantly increase the response of p/v ratio, while pH, pH*pH and
C*pH have a significantly inverse relationship with the p/v ratio.
Analysis of variance (ANOVA) indicated that the model was statistically
significant in its prediction property of the response p/v, as depicted by
a Q2 value of 0.94 (goodness of prediction). The difference (0.05) be-
tween R2 and Q2 is smaller than 0.2, suggesting that the overall model
fits well [40]. Moreover, pH and pH* pH were found to be the sig-
nificant factors for the response RSD of peak area of the API, while C
and C*C were the significant factors for migration time of API (Fig. 2b-
c). However, the response RSD of migration time does not fit regression
model, due to its insufficient prediction ability (Q2, − 0.2) and re-
producibility value of 0.44 (e.g. a numerical summary of the variability
with a limit of 0.5) [40].
In a DoE strategy, the design space is considered as a zone of ro-
bustness: no drastic changes in analytical characteristics will occur
when working within the design space. The target specifications of the
responses are defined to be: the p/v ratio, as large as possible
(minimum 1.3); the response of RSD peak area, as small as possible
(maximum 4.0); migration time, as short as possible (maximum
16min). In order to define the design space, contour plots were ana-
lyzed to visualize the individual and combined effects of BGE con-
centration and pH on the responses (Fig. 3a-c). A sweet spot plot was
adopted, which is an overlay of several response contour plots, showing
how many of the specification criteria are fulfilled (Fig. 3d). In the
Fig. 1. Electropherograms of 1.0 mg/mL L-asparaginase preparation: a) 500mM/500mM, 600mM/600mM and 800mM/800mM TRIS/boric acid of pH 8.5. API is overlaid with the
system peak under the condition of 800mM/800mM TRIS/boric acid (pH 8.5); b) pH 8.0, pH 8.25, pH 8.5 and pH 8.75 TRIS/boric acid of concentration 600mM/600mM. Impurity 1 is
overlaid with the system peak under the condition of 600mM/600mM TRIS/boric acid, pH 8.75. Imp.1 stands for impurity 1.
Fig. 2. Regression coefficients of central composite
design: a) response 1, peak to valley ratio; b) re-
sponse 2, RSD of peak area of API; c) response 3,
migration time of API.
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white, blue and green spaces, no, one or two criteria are fulfilled re-
spectively. The red space represents the sweet plot where all three
criteria are fulfilled, equivalent to the QbD design space (Fig. 3d).
Therefore, we could define the combined design space: the BGE con-
centration ranging between 350mM and 450mM (for both TRIS/boric
acid) while the pH ranging between 8.3 and 8.5. An optimal point with
a concentration of 400mM and a pH of 8.4 is proposed, which is the
middle point of the design space.
3.3. Method validation
3.3.1. Relative response factor of the acidic L-ASNase species
The mean RRF of the acidic species was calculated to be 1.01±0.02
(mean± SD, n = 2), using the 2mg/mL modified L-ASNase sample
obtained by incubating in 1% NH4HCO3 at 37 °C for 48 h. Therefore, the
factor correction is not required for the validation tests of impurity 1
and impurity 2, since the API and the impurities showed a similar UV
response. Using area normalization, 0.664mg/mL of impurity 1 and
0.516mg/mL of impurity 2 were determined in the 2mg/mL modified
sample, which is further used for the validation of impurity 1 and im-
purity 2. The peak observed at 9min is a system peak, which is also
observed in the blank. Since L-ASNase and the impurities show similar
the DAD spectra (Fig. 4), the peak purity can not be determined by
using these DAD spectra.
3.3.2. Validation results
For the selectivity, the acidic impurities 1, 2 and 3 are separated
from the API in the modified L-asparaginase (Fig. 4).
The calibration curves were found linear over a concentration range
of 0.20–1.98mg/mL for L-ASNase, 0.036–0.430mg/mL for impurity 1
and 0.023–0.135 for impurity 2. The impurity 3 is not validated, due to
its low amount (2.0%, see Section 2.1) in the native sample. The
Fig. 4. Electropherograms of 2.0 mg/mL native L-asparaginase (a) and 2.0mg/mL mod-
ified L-asparaginase (b). BGE consisting of 400mM TRIS and 400mM boric acid (pH
unadjusted, the measured pH value was pH 8.4) is applied. a: the inserted DAD spectra
(200–300 nm) obtained at the apex of the L-ASNase and impurity 1 CE-UV peaks from the
native L-ASNase. b: the inserted DAD spectra (200–300 nm) obtained at the apex of the L-
ASNase and impurity 1–3 CE-UV peaks from the modified L-ASNase.
Fig. 3. Response surface (2D) contour plots showing the effects of concentration (C) and pH on the three responses: a) peak to valley ratio; b) RSD of peak area of API; c) migration time
(min) of API; d) sweet spot of above three responses in red. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
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linearity equations and R-squared values for these three calibration
curves are presented in Table 1, where x and y are the concentration
and the peak area of the components, respectively. The method accu-
racy was calculated by comparing the found concentrations (calculated
from the calibration equation using the obtained peak area) with the
theoretical concentrations. The accuracy and precision for L-ASNase
were found to be 97.9–104.4% and 1.5–3.2% of RSD (n = 3) (Table 2)
[41]. For impurity 1, accuracy and precision were 92.1–109.8% with
1.7–4.6% of RSD. For impurity 2, accuracy and precision were
96.3–109.7% with 1.7–3.8% of RSD. For L-ASNase, LOD and LOQ were
5.7 µg/mL and 18.9 µg/mL (corresponding to 0.57% [m/m] and 1.89%
[m/m]), respectively. LOD and LOQ for impurity 1 and impurity 2 were
identical, i.e. 5.7 µg/mL and 19.1 µg/mL (corresponding to 0.57% [m/
m] and 1.91% [m/m]), respectively.
PBD was applied for assessing the robustness of the optimized CE-
UV method, with following responses: 1) RSD (%) of p/v value (defi-
nition of the resolution can be seen in Section 3.1); 2) RSD (%) of mi-
gration time of API; 3) RSD (%) of peak area of API. The target speci-
fications of each response were all defined to be maximal 3.0% (RSD).
The experimental results of each response were all located within the
specifications, which indicates a robust CE-UV method. Moreover, the
significance of the regression models for these responses had been as-
sessed by the ANOVA F-test. The p values (0.723 for RSD of p/v value,
0.948 for RSD of migration time and 0.920 for RSD of peak area of API)
indicate insignificant models, which is consistent with the regression
coefficients of each response (Fig. 5).
3.4. Application: modification rate
The optimal CZE-UV method is applied on L-ASNase, treated with
NH3HCO4 for different times to give modified samples (Fig. 6a). Ex-
ternal standardization was used for the quantification of the API, while
the internal normalization was applied for the quantification of im-
purities 1–3. External standardization was used for the quantification of
the API and impurities (1 and 2). In the unmodified L-ASNase, the
contents of API, impurity 1 and impurity 2 were calculated to be 76.8%
(RSD of 0.41%), 14.5% (RSD of 1.62%) and 4.5% (RSD of 0.84%). The
API content of modified samples decreased considerably at the first 8 h
(45.7%), followed by a more modest decrease from 8 h to 24 h (down to
35.6%) (Fig. 6b). The impurity 1 content increased steeply in the first
8 h (35.3%), after which it remained constant for 8–24 h. A pronounced
increase of impurity 2 was also observed in the first 8 h, while impurity
3 increased during the 0–24 h period within limited extent.
3.5. Enzyme activity of the modified L-ASNase and specifications
The enzymatic activity of unmodified (0 h) and modified samples
(incubated for 8 h, 16 h and 24 h) were determined to be 103.2% (RSD
of 1.75%), 101.6% (RSD of 0.35%), 99.0% (RSD of 1.08%) and 94.5%
(RSD of 0.37%) of label claim respectively. The enzyme activity of the
modified E.coli L-ASNase (containing acidic charge variants) do not
significantly differ from the unmodified E.coli L-ASNase.
4. Discussion
Our reported method is the first CZE-UV method for quantifying the
API and acidic impurities in pharmaceutical E.coli L-ASNase prepara-
tions. Even in the L-ASNase monograph from the Chinese Pharmacopeia
(ChP), there is no method or quality evaluation for these related im-
purities available [42]. Due to the hydrophobic interactions and hy-
drogen bonding, proteins often easily adsorb to the wall of fused silica
capillaries, which results in tailing peaks, poor resolution, low recovery
of the analytes and non-reproducible separations [43,44]. The adoption
of an optimized but simple BGE composition (e.g. without additive),
makes our proposed method practically very attractive. The surface
Fig. 5. Regression coefficients of Placket-Burman
design (PBD) for different responses: a) RSD (%) of
resolution; b) RSD (%) of migration time of API; c)
RSD (%) of peak area of API.
Table 1
Calibration linearity and range.
Compound Range (mg/mL) Slope Intercept R-squared
L-ASNase 0.20–1.98 2169 − 151.7 0.9978
[1984–2354]a [− 356.7 to 53.4]b
Impurity 1 0.036–0.430 2329 − 52.0 0.9953
[2036–2622]a [− 119.4 to 15.3]b
Impurity 2 0.023–0.135 1576 11.0 0.9912
[1304–1849]a [− 8.8 to 30.9]b
a 95% CI (confidence interval) of the slope.





Mean recovery % (n =
3)
Precision RSD %(n = 3)
L-ASNase 0.396 97.9 3.2
0.791 102.2 2.9
1.187 104.4 1.5
Impurity 1 0.072 92.1 4.6
0.144 98.1 2.4
0.215 109.8 1.7
Impurity 2 0.034 96.3 1.7
0.045 99.8 3.2
0.068 109.7 3.8
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silanol groups of the fused silica capillary are slightly acidic; hence are
negatively charged in BGE at the applied high pH value, creating an
electrical double layer with cations pulling all species towards the
cathode [45]. Due to this overwhelming electroosmotic flow (EoF) and
the opposite electrophoretic mobility of the more negatively charged
acidic variants, the acidic variants migrate slower in the capillary
moving to the cathode, compared to the native L-ASNase.
The validation results indicated that the developed CZE-UV method
was selective, accurate, precise, robust and was linear in the calibration
range for the API and the impurities. In the application Section 3.4.),
the area normalization without factor correction was used for the
quantification of the impurities (1, 2 and 3), while external standardi-
zation was used for the quantification of the API. As the responses of the
impurities were close to the API (i.e. response factor in the range of
0.8–1.2), correction factors were not required during the internal nor-
malization [37].
Deamidated variants are a common acidic variant occurring in the
biopharmaceutical proteins [46]. The acidic species in the Erwinia L-
ASNase was demonstrated to be deamidated species [13]. Moreover,
NH4HCO3 induced acidic variants are deamidated species, according to
previous studies [13,47]. The active, tetrameric form of L-ASNase is
composed of four identical subunits. One subunit consists of two α/β
domains, i.e. N-terminal domain and C-terminal domain (both all par-
allel α/β structures), connected by the linking sequence 191–212 [48].
The active site or ligand binding pocket, composed of Thr12, Tyr25,
Ser58, Thr89, Asp90 and Lys162, is located between the clefts formed by
Fig. 7. Three-dimensional structure of E.coli L-ASNase with space
fill representations of Asn184 in red and Asn246 in blue (one
monomer in green and the other three monomers in grey): a)
tetramer; b) dimer; c) dimer rotating 90° to the left; d) monomer.
C and N represent C-terminus and N-terminus respectively, which
were colored in purple. A, B, C and D in brackets represent four
individual monomers, respectively. The image is created with the
UCSF Chimera programme (San Francisco, USA), by using the
Protein Data Bank (PDB) structure file 3ECA. (For interpretation
of the references to color in this figure legend, the reader is re-
ferred to the web version of this article.)
Fig. 6. Modification rate: a) electropherograms of 1.0mg/mL modified L-asparaginase sample (incubated for 0, 8, 16 and 24 h); b) time-content curve of L-asparaginase (API) and impurity
1–3. BGE consisting of 400mM TRIS and 400mM boric acid (pH unadjusted, the measured pH value was pH 8.4) is applied.
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each N-terminal domain [48,49]. The deamidation rate of Asn is in-
fluenced by the amino acid residue at the C-terminal side of Asn, with
proteins and peptides with the Asn-Gly sequence showing the highest
(70×) deamidation rates [50]. E.coli L-ASNase monomer contains 23
Asn residues, but only two Asn have a C-terminal Gly, i.e. Asn184 and
Asn246 (Fig. 7). Asn184 and Asn246 are located in the N-terminal domain
and C-terminal domain, respectively. The partially charged E.coli L-
ASNase would be related to the Asn184 and Asn246 deamidation.
The observed slight decrease in enzyme activity of modified E.coli L-
ASNase sample (i.e. 94.5% after 24 h incubation) might however not
significantly influence the clinical efficacy. According to the limited
clinical data, a wide range of dosages and schedules are able to achieve
complete L-Asn depletion in serum and cerebrospinal fluid [51]. In
addition, a relatively wide enzymatic activity specification is described
in the ChP, which is currently the only Pharmacopeia including a L-
ASNase monograph, i.e. 85–115% of label claim [42]. Clinical efficacy
of E.coli L-ASNase preparations containing limited quantities of charge
variants, as well as other aspects such as safety, remains to be further
investigated to justify an appropriately quantified acceptance limit for
the charge variants.
5. Conclusion
In this study, a CZE-UV method for the quantification of both the
E.coli L-ASNase API and the acidic impurities was developed and vali-
dated using a QbD strategy. The application of L-ASNase modified
samples indicated that the proposed CZE-UV approach is efficient to
determine the API and the acidic impurities in the unmodified and
partially modified L-ASNase. Moreover, the functional in-vitro enzyme
activity of modified E.coli L-ASNase samples was evaluated, indicating
an insignificant difference between the partially charged E.coli L-
ASNase with the unmodified L-ASNase. We suggest this CZE-UV method
can be adopted as a pharmaceutical quality control method.
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